Logo

Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC

Share this

Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC

Shots:

  • The P-III IMpower010 involves assessing Tecentriq + BSC in 1-005 participants in a ratio (1:1) with Stage IB-IIIA NSCLC- following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
  • Results: 34% reduction in risk of death in people with Stage II-IIIA NSCLC. In the larger population of all randomized Stage II-IIIA study patients showed a 21% reduction in risk of disease recurrence or death after a median follow-up of 32.2mos- DFS (42.3mos. vs 35.3mos.)- no new safety signals were observed
  • Tecentriq is the first and only cancer immunotherapy to show positive P-III results in the adjuvant lung cancer setting

  Ref: Businesswire | Image: Center for Health Journalism

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions